Jefferies Group Equities Analysts Lift Earnings Estimates for Anthera Pharmaceuticals, Inc. (ANTH)
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) – Research analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for shares of Anthera Pharmaceuticals in a research report issued to clients and investors on Wednesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings per share of ($2.95) for the year, up from their prior estimate of ($3.43). Jefferies Group has a “Hold” rating and a $1.75 price target on the stock. Jefferies Group also issued estimates for Anthera Pharmaceuticals’ Q4 2017 earnings at ($1.03) EPS, FY2018 earnings at ($3.73) EPS, FY2019 earnings at ($5.33) EPS, FY2020 earnings at ($3.10) EPS and FY2021 earnings at ($0.03) EPS.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.32. During the same period last year, the firm earned ($4.85) earnings per share. COPYRIGHT VIOLATION WARNING: This article was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/11/17/jefferies-group-equities-analysts-lift-earnings-estimates-for-anthera-pharmaceuticals-inc-anth.html.
A number of other analysts have also recently issued reports on the company. Zacks Investment Research cut Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. Finally, ValuEngine raised Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $5.11.
Anthera Pharmaceuticals (NASDAQ:ANTH) traded down $0.03 on Friday, hitting $2.21. The stock had a trading volume of 467,076 shares, compared to its average volume of 340,675. Anthera Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $20.24.
A number of large investors have recently added to or reduced their stakes in the stock. UBS Group AG lifted its holdings in Anthera Pharmaceuticals by 9.9% during the 1st quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 33,901 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Anthera Pharmaceuticals by 1,376.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 335,595 shares during the last quarter. Finally, Wedbush Securities Inc. lifted its holdings in Anthera Pharmaceuticals by 75.8% during the 3rd quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 31,800 shares during the last quarter. 26.10% of the stock is owned by institutional investors and hedge funds.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.